Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective

References

• Poewe W, Wenning G. The differential diagnosis of Parkinson’s disease. Eur J Neurol. 2002;9(Suppl 3):23–30.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology. 2001;57:1497–1499.
   PubMed Web of Science ®Google Scholar
• GE Healthcare. Protocol manual for DaTscan (Ioflupane I123 injection). Last revised 2011. [cited 2016 Oct 5]. Available from: http://us.datscan.com/wp-content/uploads/2016/07/JB39854US-US-DaTscan-Protocol-Manual-digital-secure.pdf
   Google Scholar
• Oravivattanakul S, Benchaya L, Wu G, et al. Dopamine Transporter (DaT) scan utilization in a movement disorder center. Mov Disord Clin Pract. 2015;3:1–5.
   Web of Science ®Google Scholar
• Brooks DJ, Tambasco N. Imaging synucleinopathies. Mov Disord. 2016;31(6):814–829.
   PubMed Web of Science ®Google Scholar
• Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5–12.
   PubMed Web of Science ®Google Scholar
• Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–510.
   PubMed Web of Science ®Google Scholar
• Varrone A, Dickson JC, Tossici-Bolt L, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213–227.
   PubMed Web of Science ®Google Scholar
• Nicastro N, Garibotto V, Poncet A, et al. Establishing On-site reference values for (123)I-FP-CIT SPECT (DaTSCAN®) using a cohort of individuals with non-degenerative conditions. Mol Imaging Biol. 2016;18:302–312.
   PubMed Web of Science ®Google Scholar
• Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1995;59:597–600.
   PubMed Web of Science ®Google Scholar
• Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology. 2001;57:2089–2094.
   PubMed Web of Science ®Google Scholar
• Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–450.
   PubMed Web of Science ®Google Scholar
• Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med (Lond). 2016;16:371–375.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–1601.
   PubMed Web of Science ®Google Scholar
• Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord. 2002;17:45–53.
   PubMed Web of Science ®Google Scholar
• Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9–24.
   PubMedGoogle Scholar
• Antonini A, Benti R, De Notaris R, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149–150.
   PubMed Web of Science ®Google Scholar
• Pirker W, Asenbaum S, Bencsits G, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158–1167.
   PubMed Web of Science ®Google Scholar
• Booth TC, Nathan M, Waldman AD, et al. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2. AJNR Am J Neuroradiol. 2015;36:236–244.
   PubMed Web of Science ®Google Scholar
• Wenning GK, Krismer F. Multiple system atrophy. Handb Clin Neurol. 2013;117:229–241.
   PubMedGoogle Scholar
• Sadasivan S, Friedman JH. Experience with DaTscan at a tertiary referral center. Parkinsonism Relat Disord. 2015;21:42–45.
   PubMed Web of Science ®Google Scholar
• Bega D, Gonzalez-Latapi P, Zadikoff C, et al. Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice?. Neurodegener Dis. 2015;15:81–86.
   PubMed Web of Science ®Google Scholar
• Gayed I, Joseph U, Fanous M, et al. The impact of DaTscan in the diagnosis of Parkinson disease. Clin Nucl Med. 2015;40:390–393.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Porcel F, Jamali S, Duker AP, et al. Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user’s guide. Expert Rev Neurother. 2016;16(1):23-29.
   Web of Science ®Google Scholar
• Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patientswith suspected parkinsonian syndromes. J Neuroimaging. 2012;22:225–230.
   PubMed Web of Science ®Google Scholar
• Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175–1182.
   PubMed Web of Science ®Google Scholar
• Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry. 2012;83:620–628.
   PubMed Web of Science ®Google Scholar
• Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010;25:534–541.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Elble R. Essential tremor–neurodegenerative or nondegenerative disease towards a working definition of ET. Mov Disord. 2009;24:2033–2041.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord. 1998;13(Suppl 3):2–23.
   PubMed Web of Science ®Google Scholar
• Thenganatt MA, Louis ED. Distinguishing essential tremor from Parkinson’s disease: bedside tests and laboratory evaluations. Expert Rev Neurother. 2012;12:687–696.
   PubMed Web of Science ®Google Scholar
• Vlaar AM, van Kroonenburgh MJ, Kessels AG, et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol. 2007;7:27.
   PubMed Web of Science ®Google Scholar
• Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007;22:2210–2215.
   PubMed Web of Science ®Google Scholar
• Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85:759–769.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Auinger P, Oakes D, et al. Levodopa response in early Parkinson’s disease. Mov Disord. 2009;24:2328–2336.
   PubMed Web of Science ®Google Scholar
• Suchowersky O, Reich S, Perlmutter J, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:968–975.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361:1268–1278.
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508.
   PubMed Web of Science ®Google Scholar
• Marjama-Lyons J, Koller W. Tremor-predominant Parkinson’s disease. Approaches to treatment. Drugs Aging. 2000;16:273–278.
   PubMed Web of Science ®Google Scholar
• Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2007;78:465–469.
   PubMed Web of Science ®Google Scholar
• Caligiuri MP, Bracha HS, Lohr JB. Asymmetry of neuroleptic-induced rigidity: development of quantitative methods and clinical correlates. Psychiatry Res. 1989;30:275–284.
   PubMed Web of Science ®Google Scholar
• Arblaster LA, Lakie M, Mutch WJ, et al. A study of the early signs of drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 1993;56:301–303.
   PubMed Web of Science ®Google Scholar
• Morgante F, Edwards MJ, Espay AJ. Psychogenic movement disorders. Continuum (Minneap Minn). 2013;19:1383–1396.
   PubMedGoogle Scholar
• Schrag A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol. 2005;18:399–404.
   PubMed Web of Science ®Google Scholar
• Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol. 2009;22:430–436.
   PubMed Web of Science ®Google Scholar
• Benaderette S, Zanotti Fregonara P, Apartis E, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord. 2006;21:310–317.
   PubMed Web of Science ®Google Scholar
• Gaig C, Marti MJ, Tolosa E, et al. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord. 2006;21:1994–1998.
   PubMed Web of Science ®Google Scholar
• Fereshtehnejad SM, Romenets SR, Anang JB, et al. New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72:863–873.
   PubMed Web of Science ®Google Scholar
• Jennings DL, Seibyl JP, Oakes D, et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004;61:1224–1229.
   PubMedGoogle Scholar
• Marshall VL, Reininger CB, Marquardt M, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24:500–508.
   PubMed Web of Science ®Google Scholar
• Marshall VL, Patterson J, Hadley DM, et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun. 2006;27:933–937.
   PubMed Web of Science ®Google Scholar
• Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology. 2014;83:1739–1746.
   PubMed Web of Science ®Google Scholar